Results 171 to 180 of about 11,407 (210)

A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae. [PDF]

Microbiol Spectr
Qiao S, Xin S, Zhu Y, Zhao F, Wu H, Zhang J, Yao B, Yu Y, Fu Y, Jiang Y, Xie X, Zhang J.   +11 more
europepmc   +1 more source

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15) [PDF]

, 2017
Bassetti, Matteo, Castanheira, Mariana, Duncan, Leonard R., Pfaller, Michael A.   +3 more
core   +1 more source

In vivo evolution to hypermucoviscosity and ceftazidime/avibactam resistance in a liver abscess caused by Klebsiella pneumoniae sequence type 512. [PDF]

mSphere
Capitani V, Arcari G, Ambrosi C, Scribano D, Ceparano M, Polani R, De Francesco A, Raponi G, Ceccarelli G, Villari P, Palamara AT, Marzuillo C, Carattoli A.   +12 more
europepmc   +1 more source

First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197. [PDF]

Microbiol Spectr
De la Cadena E, Mojica MF, Rojas LJ, Castro BE, García-Betancur JC, Marshall SH, Restrepo N, Castro-Caro NP, Fonseca-Carrillo M, Pallares C, Bonomo RA, Villegas MV.   +11 more
europepmc   +1 more source

Evolution of ceftazidime-avibactam resistance driven by variation in <i>bla</i> _KPC-2 to <i>bla</i> _KPC-190 during treatment of ST11-K64 hypervirulent <i>Klebsiella pneumoniae</i>. [PDF]

Front Cell Infect Microbiol
Liu Z, Lei J, Zhang X, Yin J, Zhang Y, Lei K, Geng Y, Huang L, Han Q, He A.   +9 more
europepmc   +1 more source

Mechanisms leading to <i>in vivo</i> ceftazidime/avibactam resistance development during treatment of GES-5-producing <i>Pseudomonas aeruginosa</i> infections. [PDF]

Antimicrob Agents Chemother
Herrera C, Gomis-Font MA, López-Causapé C, Díez-Aguilar M, Fraile-Ribot PA, Cardeñoso LM, Oliver A.   +6 more
europepmc   +1 more source

Correction for Qiao et al., "A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated <i>Klebsiella pneumoniae</i>". [PDF]

Microbiol Spectr
Qiao S, Xin S, Zhu Y, Zhao F, Wu H, Zhang J, Yao B, Yu Y, Fu Y, Jiang Y, Xie X, Zhang J.   +11 more
europepmc   +1 more source

A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing <i>Klebsiella pneumoniae</i> infections and on ceftazidime/avibactam resistance development. [PDF]

Antimicrob Agents Chemother
Gatti M, Rinaldi M, Cojutti PG, Bonazzetti C, Siniscalchi A, Tonetti T, Ambretti S, Tedeschi S, Giannella M, Viale P, Pea F.   +10 more
europepmc   +1 more source

Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa. [PDF]

Front Cell Infect Microbiol
Soto KD, Alcalde-Rico M, Ugalde JA, Olivares-Pacheco J, Quiroz V, Brito B, Rivas LM, Munita JM, García PC, Wozniak A.   +9 more
europepmc   +1 more source

Overexpression of <i>bla</i>_SHV-12 caused by tandem amplification contributed to ceftazidime/avibactam resistance in hypervirulent and carbapenem-resistant <i>Klebsiella pneumoniae</i>. [PDF]

Emerg Microbes Infect
Liu C, Yi J, Yang P, Du C, Jiang F, Lu M, Du P, Shen N.   +7 more
europepmc   +1 more source